Table 1.
Change in MB IC50 in 24h treatments of stage V gametocytes in co-incubation with redox perturbing compounds.
| Compound code | Description and role on redox | IC50 MB alone*/IC50 MB + compound (1 μM) | IC50 of compound alone |
|---|---|---|---|
| Benzylmenadione 1c (Müller et al., 2011) | Plasmodione (redox cycler and ROS inducer) | 0.95 | >20μM |
| Benzoylmenadione 3c (Müller et al., 2011) | Plasmodione metabolite I (redox cycler or GR substrate) | 0.95 | >20μM |
| Benzylmenadione 17e (Cesar Rodo et al., 2016) | 6-Fluoro- plasmodione (analogue 17e of plasmodione) | 0.74 | >20μM |
| M5 (Salmon-Chemin et al., 2001; Davioud-Charvet et al., 2001; Biot et al., 2004) | Menadione derivative (GR inhibitor) | 0.60 | >20μM |
| Benzylmenadione 3f (Müller et al., 2011) | Menadione derivative (GR inhibitor) | 1.03 | >20μM |
| paracetamol (Forrest et al., 1982) | Acetaminophen (glutathione depletor) | 0.41 | >20μM |
| ML304 (Maloney et al., 2012) | (R)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-methyl-11-oxo-10,11-Dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide (PfGluPho inhibitor) | 17.88 | >20μM |
*
The reference IC50 for a 24h treatment with MB alone is 4.65 μM.